Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation
AbstractFactor Xa (FXa) plays a significant role in the blood coagulation cascade and it has become a promising target for anticoagulation drugs. Three oral direct FXa inhibitors have been approved by the FDA for treating thrombotic diseases. By structure-activity relationship (SAR) analysis upon these FXa inhibitors, a series of novel anthranilamide-based FXa inhibitors were designed and synthesized. According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent selectivity over thrombin in in vitro inhibition activities studies. Compounds 1g and 1s also exhibited pronounced anticoagulant activities in in vitro anticoagulant activity studies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Wang, W.; Yuan, J.; Fu, X.; Meng, F.; Zhang, S.; Xu, W.; Xu, Y.; Huang, C. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Molecules 2016, 21, 491.
Wang W, Yuan J, Fu X, Meng F, Zhang S, Xu W, Xu Y, Huang C. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation. Molecules. 2016; 21(4):491.Chicago/Turabian Style
Wang, Wenzhi; Yuan, Jing; Fu, Xiaoli; Meng, Fancui; Zhang, Shijun; Xu, Weiren; Xu, Yongnan; Huang, Changjiang. 2016. "Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation." Molecules 21, no. 4: 491.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.